Skip to main content

Table 2 Information of envelopes used for assays

From: Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge

Env ID Clade Location Mode of transmission Length of infection Mo/yr isolated Corecepter
Du172.17 C South Africa M-F 12 weeks Nov-98 R5
ZM214M.PL15 C Zambia F-M <13 weeks Jul-03 R5
CAP210.2.00.E8 C South Africa M-F 5 weeks May-05 R5
CHN19 C China     R5
HIV16936-2 EF117270 C India F-M 1 week Nov-00 R5
Q168.ENV.B23 A Kenya M-F 1 week   R5
Q461.ENV.C2 A Kenya M-F 4 weeks   R5
HIV env 6235 clone 3 B USA M-M 6 weeks Mar-95 R5
PVO clone 4 B Italy M-M 4 weeks Jan-96 R5
pRHPA 4259 clone7 B USA M-F < weeks Dec-00 R5
pTHRO4156 clone 18 B USA M-M 1 week Aug-00 R5
SC 422661.8 B Trinidad F-M 4 weeks Jan-95 R5
SF162 B USA     R5
93TH975-15 E Haiti F-M <18 weeks Jan-93 R5
  1. Primary envelopes from various clade was chosen based to have a diversity of locations and mode of mocusal transmission. Envelopes were used to test the presence of binding and neutralizing antibodies elicited by vaccination of consensus vaccines in non-human primates. SF162 was included because it is the challenge virus envelope.